AMC Networks price target lowered to $6 from $8 at JPMorgan
JPMorgan analyst David Karnovsky lowered the firm's price target on AMC Networks (AMCX) to $6 from $8 and keeps an Underweight rating on the shares. The firm reduced estimates following the company's Q1 report. It sees limited room for a stock re-rating amid continued pressure to AMC's core revenue streams.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Any near-term weakness in S&P 500 would provide a 'buy the dip' opportunity: JPM
-- JPMorgan analysts said in a note Wednesday that while the recent equity market rebound has lost momentum, any short-term pullback in large-cap stocks should be viewed as a 'buy the dip' opportunity. 'Equity rebounds have either decelerated or stalled since mid-May,' JPMorgan wrote. 'The associated signals increase the probability for corrective price action over the near term.' However, the bank's analysts maintained a bullish stance on large caps, citing strong medium-term trend dynamics. 'That bullish medium-term outlook stays in gear provided the S&P 500 Index holds above key levels in the 5600s,' stated JPMorgan. The bank added that large-cap leadership remains intact and that 'we suspect any near-term weakness in large-cap equities will provide a 'buy the dip' opportunity ahead of a potential test of the cycle highs at some point this summer.' JPMorgan also flagged signs of exhaustion in more cyclical parts of the market, noting that the Russell 2000, Materials, and Energy sectors have stalled near key resistance. 'Commodity price action reinforces the signaling for those two sectors,' the firm added, highlighting DuPont (NYSE:DD) and EOG Resources (NYSE:EOG) as examples of weaker setups within those groups. Conversely, JPMorgan pointed to healthcare as a potential bright spot if broader markets weaken. 'We also see the beaten up Healthcare sector as an interesting long opportunity,' analysts wrote, citing recent buy signals and proximity to support levels. Bristol Myers (NYSE:BMY) Squibb was noted as a stock with an 'attractive setup and chart pattern.' Related articles Any near-term weakness in S&P 500 would provide a 'buy the dip' opportunity: JPM UBS upgrades Snowflake on signs of sustained data infrastructure investment Trump urges Fed Chair Powell to cut rates after ADP jobs data release Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
3D Systems collaborates with Penn State, ASU researchers on NASA projects
3D Systems (DDD) is collaborating with researchers from Penn State University and Arizona State University on two projects sponsored by the National Aeronautics & Space Administration intended to enable ground-breaking alternatives to current thermal management solutions. Severe temperature fluctuations in space can damage sensitive spacecraft components, resulting in mission failure. By combining deep applications expertise with 3D Systems' leading additive manufacturing solutions comprising Direct Metal Printing technology and tailored materials and Oqton's 3DXpert software, the teams are engineering sophisticated thermal management solutions for the demands of next-generation satellites and space exploration. The project led by researchers with Penn State University, Arizona State University, and the NASA Glenn Research Center1 in collaboration with 3D Systems' Application Innovation Group has resulted in processes to build embedded high-temperature passive heat pipes in heat rejection radiators that are additively manufactured in titanium. These heat pipe radiators are 50% lighter per area with increased operating temperatures compared with current state-of-the-art radiators, allowing them to radiate heat more efficiently for high power systems. Additionally, a project led by researchers at Penn State University and NASA Glenn Research Center with 3D Systems' AIG yielded a process to additively manufacture one of the first functional parts using nickel titanium shape memory alloys that can be passively actuated and deployed when heated. This passive shape memory alloy radiator is projected to yield a deployed-to-stowed area ratio that is 6x larger than currently available solutions, enabling future high-power communications and science missions in restricted CubeSat volume. When deployed on spacecraft, such as satellites, these radiators can raise operating power levels and reduce thermal stress on sensitive components, preventing failures and prolonging satellite lifespan. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DDD: Disclaimer & DisclosureReport an Issue 3D Systems Adjusts Equity Awards Amid Stockholder Meeting 3D Systems Corp Navigates Challenges with Strategic Focus 3D Systems Faces Persistent Revenue Challenges Despite Restructuring and Asset Sale, Justifying Hold Rating 3D Systems Reports Q1 2025 Financial Results 3D Systems' Financial Struggles Lead to Hold Rating Amid Revenue Declines and Withdrawn Guidance
Yahoo
an hour ago
- Yahoo
60 Degrees announces results from an insurance claims analysis on babesiosis
60 Degrees Pharmaceuticals (SXTP) announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health. Results showed approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs each year, according to 60 Degrees Pharmaceuticals. In contrast, current estimates published by the Centers for Disease Control and Prevention show only 2,000 cases in 2020. Babesia infections last at least 12 months in 14 percent of patients and may relapse up to 27 months later, as documented in the scientific literature. Many physicians treating tick-borne infections speculate the true duration of infection may be much longer. The claims data indicated approximately 31 percent of babesiosis cases persist longer than 30 days, and that nearly half of those are associated with chronic fatigue lasting longer than six months. Fatigue is the last symptom of babesiosis to resolve in acute disease. Chronic fatigue during babesiosis has not been systematically described in the literature. Further, the claims data, which captured approximately 40 percent of U.S. diagnostic data, showed that over three years, more than 12 million U.S. adults experienced chronic fatigue greater than six months in duration. Current Infectious Diseases Society of America advice and other professional guidelines do not mandate babesiosis as a differential diagnosis if a patient self-reports experiencing such fatigue. The Company is testing, through its clinical development program, the medical hypothesis that the true burden of babesiosis is much larger than claims data suggest and is a function of the incidence of chronic fatigue lasting six months or longer, multiplied by the proportion of such individuals with confirmable infections. A molecular incidence study in patients with chronic fatigue commissioned by the Company was recently completed. Once published, the data will allow establishment of a ceiling on the incidence of persistent babesiosis. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SXTP: Disclaimer & DisclosureReport an Issue 60 Degrees announces findings from online survey about babesiosis disease 60 Degrees Pharmaceuticals signs Patient License Agreement with Yale
